Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone

Abstract

suppress the gradual progression of renal impairment and, in the present study, investigated the effect of esaxerenone therapy on the preservation of eGFR by comparing a period prior to esaxerenone therapy (pre-treatment period) to a period on esaxerenone among a hypertensive cohort. Methods Patient SelectionConsecutive patients who received esaxerenone for the treatment of resistant hypertension between November 2019 and June 2020 were considered for inclusion in this retrospective study. Patients with an eGFR <30 mL/min/ 1.73 m 2 or those with serum potassium >5.0 mEq/L were not given esaxerenone. Patients with malignancy or secondary hypertension were excluded from the study. Patients without comprehensive clinical data obtained at 3 time points (in the 6 months before esaxerenone, at baseline, and after 6 months esaxerenone treatment) were also excluded. The study protocol was approved by the University of Toyama Ethics Committee (No. RCOI2019584). All participants

Adaptive Servo-Ventilation as a Novel Therapeutic Strategy for Chronic Heart Failure

“…Although further studies are needed, sacubitril/valsartan might also slow the worsening of renal function through an improvement in ventricular function and lowering the volume and pressure burden experienced by kidneys [31]. Although categorized as a mineralocorticoid receptor antagonist, the newly introduced esaxerenone might reduce proteinuria and better preserve renal function [32]. Another nonsteroidal, selective mineralocorticoid receptor antagonist, finerenone, may also suppress progression of chronic kidney disease and prevent cardiovascular events [33].…”